List of nationally authorised medicinal products

Size: px
Start display at page:

Download "List of nationally authorised medicinal products"

Transcription

1 30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.

2 Member where Sporanox 10 mg/ml Lösung UK/H/0158/001 BE JANSSEN-CILAG NV BE zum Einnehmen Sporanox 10 mg/ml oral UK/H/0158/ JANSSEN-CILAG OY FI lösning Sporanox 10 mg/ml Lösung UK/H/0158/ JANSSEN-CILAG NV LU zum Einnehmen SPORANOX 10 mg/ml Oral UK/H/0158/001 PL 00242/0307 JANSSEN-CILAG LIMITED UK Solution. SPORANOX 10 mg/ml solution UK/H/0158/ JANSSEN-CILAG NV LU buvable Sporanox 10 mg/ml Lösung UK/H/0158/ JANSSEN-CILAG PHARMA AT zum Einnehmen GMBH Sporanox 10 mg/ml oral UK/H/0158/ JANSSEN-CILAG AB SE lösning SPORANOX 10 mg/ml UK/H/0158/ JANSSEN-CILAG OY FI oraaliliuos Sempera Liquid 10 mg/ml, UK/H/0158/ JANSSEN-CILAG GMBH DE Lösung zum Einnehmen SPORANOX 10 mg/ml Oral UK/H/0158/001 PA 0748/009/001 JANSSEN-CILAG LIMITED IE Solution. SPORANOX 10 mg/ml solution UK/H/0158/001 BE JANSSEN-CILAG NV BE buvable SPORANOX 10 mg/ml, drank. UK/H/0158/001 BE JANSSEN-CILAG NV BE Trisporal O.S.-drank 10 mg/ml, drank. SPORANOX 10 mg/ml soluzione orale UK/H/0158/001 RVG JANSSEN-CILAG BV NL UK/H/0158/ /M JANSSEN-CILAG SPA IT EMA/817337/2017 Page 2/8

3 Member where SPORANOX 10 mg/ml Solução UK/H/0158/ JANSSEN FARMACÊUTICA PT Oral Sporanox 100 mg Hartkapseln not available BE JANSSEN-CILAG NV BE Sporanox 100 mg kapsel, hård not available JANSSEN-CILAG OY FI SPORANOX 100 mg, gélule not available JANSSEN-CILAG FR SPORANOX 100 mg, gélule not available JANSSEN-CILAG FR SPORANOX 100 mg, gélule not available JANSSEN-CILAG FR SPORANOX 100 mg, gélule not available JANSSEN-CILAG FR SPORANOX 100 mg, gélule not available JANSSEN-CILAG FR SPORANOX 100 mg, gélule not available JANSSEN-CILAG FR Sporanox 100 mg Hartkapseln not available JANSSEN-CILAG NV LU SPORANOX 100 mg capsule not available JANSSEN-CILAG SPA IT rigide SIROS Kapseln, 100 mg not available JANSSEN-CILAG GMBH DE Hartkapseln SPORANOX 100 mg kapsuly not available 26/0194/90-C/S JOHNSON & JOHNSON, S.R.O SK SPORAL 100mg Capsules. not available 018/02401 JANSSEN-CILAG INTERNATIONAL NV MT EMA/817337/2017 Page 3/8

4 Member where SPORAL 100mg Capsules. not available 018/02401 JANSSEN-CILAG MT INTERNATIONAL NV SEMPERA 7 Kapseln, 100 mg not available JANSSEN-CILAG GMBH DE Hartkapseln Orungal 100 mg kemény not available OGYI-T-2172/03 JANSSEN-CILAG KFT. HU kapszula Orungal 100 mg kemény not available OGYI-T-2172/02 JANSSEN-CILAG KFT. HU kapszula Orungal 100 mg kemény not available OGYI-T-2172/01 JANSSEN-CILAG KFT. HU kapszula Orungal 100 mg capsule not available 4909/2004/02 JANSSEN PHARMACEUTICA NV RO SPORAL 100 mg Capsules not available JANSSEN-CILAG CY INTERNATIONAL NV Trisporal 100 mg capsules, not available RVG JANSSEN-CILAG BV NL hard. SPORANOX 100 mg, gélules not available JANSSEN-CILAG NV LU Sporanox, kapsler not available JANSSEN-CILAG A/S DK SPORANOX 10 mg/ml, solution not available JANSSEN-CILAG FR buvable Sporanox 100 mg Capsules not available PL 00242/0142 JANSSEN-CILAG LIMITED UK SPORANOX 10 mg/ml perorální roztok SPORANOX 100 mg capsules, hard not available 26/1097/97-C JANSSEN-CILAG S.R.O CZ not available BE JANSSEN-CILAG NV BE EMA/817337/2017 Page 4/8

5 Member where SPORANOX 100 mg, gélules not available BE JANSSEN-CILAG NV BE ORUNGAL, 100 mg, kapsułki not available R/0043 JANSSEN-CILAG PL INTERNATIONAL NV Sporanox 100 mg kapsel, hard not available 8158 JANSSEN-CILAG A/S NO Trisporal IV 10 mg/ml not available RVG JANSSEN-CILAG BV NL concentraat en oplosmiddel voor oplossing voor infusie Sporanox DERM 100 mg not available JANSSEN-CILAG PHARMA AT Kapseln GMBH SPORANOX 10 mg/ml πόσιμο not available 39720/10/ JANSSEN-CILAG GR διάλυμα PHARMACEUTICAL C.I. Sporanox-Pulse not available PL 00242/0334 JANSSEN-CILAG LIMITED UK Sporanox 100 mg Kapseln not available JANSSEN-CILAG PHARMA AT GMBH SPORANOX 100 mg, gélule not available JANSSEN-CILAG FR SEMPERA Kapseln, 100 mg not available JANSSEN-CILAG GMBH DE Hartkapseln Sporanox 100 mg hylki, hörð. not available JANSSEN-CILAG AB IS Sporanox 100 mg hårda not available JANSSEN-CILAG AB SE kapslar SPORANOX 100mg Capsules not available PA 0748/009/002 JANSSEN-CILAG LIMITED IE EMA/817337/2017 Page 5/8

6 Member where SPORANOX 10 mg/ml not available 5363-I-32/08 JOHNSON & JOHNSON SI peroralna raztopina PRODAJA MEDICINSKIH IN FARMACEVTSKIH IZDELKOV, D.O.O. SPORANOX 100 mg trde not available 5363-I-433/10 JOHNSON & JOHNSON SI kapsule PRODAJA MEDICINSKIH IN FARMACEVTSKIH IZDELKOV, D.O.O. SPORANOX 100 mg trde not available 5363-I-365/12 JOHNSON & JOHNSON SI kapsule PRODAJA MEDICINSKIH IN FARMACEVTSKIH IZDELKOV, D.O.O. SPORANOX 100 MG καψάκια not available 39717/10/ JANSSEN-CILAG GR σκληρά PHARMACEUTICAL C.I. SPORANOX 100 mg trde not available 5363-I-434/10 JOHNSON & JOHNSON SI kapsule PRODAJA MEDICINSKIH IN FARMACEVTSKIH IZDELKOV, D.O.O. Sporanox 100 mg cápsulas not available JANSSEN FARMACÊUTICA PT Sporanox 100 mg cápsulas not available JANSSEN FARMACÊUTICA PT Sporanox 100 mg cápsulas not available JANSSEN FARMACÊUTICA PT Sporanox 100 mg cápsulas not available JANSSEN FARMACÊUTICA PT Sporanox 100 mg kapseli, kova not available JANSSEN-CILAG OY FI EMA/817337/2017 Page 6/8

7 Member where SPORANOX 100 mg cápsulas not available JANSSEN-CILAG ES Orungal 100 mg capsule not available 4909/2004/03 JANSSEN PHARMACEUTICA NV RO Orungal 100 mg capsule not available 4909/2004/01 JANSSEN PHARMACEUTICA NV RO Micogal 100 mg capsule not available 7080/2014/01 S.C. ROMPHARM COMPANY RO S.R.L. SPORANOX IV 10 mg/ml UK/H/0158/ /M JANSSEN-CILAG SPA IT concentrato e solvente, soluzione per infusione Sempera 10 mg/ml Konzentrat UK/H/0158/ JANSSEN-CILAG GMBH DE und Lösungsmittel zur Herstellung einer Infusionslösung Sporanox IV 10 mg/ml UK/H/0158/002 PL 00242/0344 JANSSEN-CILAG LIMITED UK concentrate and solvent for solution for infusion. SPORANOX IV 10 mg/ml UK/H/0158/002 PA 748/9/4 JANSSEN-CILAG LIMITED IE concentrate and solvent for solution for infusion. SPORANOX I.V. 10 mg/ml UK/H/0158/ JANSSEN-CILAG GR πυκνό διάλυμα και διαλύτης για παρασκευή διαλύματος προς έγχυση PHARMACEUTICAL C.I. SPORANOX IV 10 mg/ml, concentrado e solvente para solução para perfusão. UK/H/0158/ JANSSEN FARMACÊUTICA PT EMA/817337/2017 Page 7/8

8 Member where ITRAGERM 50 mg cápsulas UK/H/4345/ MAYNE PHARMA UK LIMITED ES duras ITRAISDIN 50 mg Hartkapseln UK/H/4345/ ISDIN GMBH DE Mytra 50 mg Hartkapseln UK/H/4345/ A-MED GMBH AT LOZANOC 50 mg hard capsules UK/H/4345/01/DC PL 37190/0001 MAYNE PHARMA UK LIMITED UK CANADIOL 10 mg/ml solución not available LABORATORIOS DR. ESTEVE ES oral CANADIOL 100 mg cápsulas not available LABORATORIOS DR. ESTEVE ES CANADIOL 10 mg/ml solución not available LABORATORIOS DR. ESTEVE ES oral CANADIOL 100 mg cápsulas not available LABORATORIOS DR. ESTEVE ES CANADIOL 10 mg/ml solución not available LABORATORIOS DR. ESTEVE ES oral CANADIOL 100 mg cápsulas not available LABORATORIOS DR. ESTEVE ES TRIASPORIN 100 mg capsule not available ITALFARMACO S.P.A IT rigide TRIASPORIN 10 mg/ml not available ITALFARMACO S.P.A IT soluzione orale Hongoseril 100 mg cápsulas not available ISDIN, ES EMA/817337/2017 Page 8/8

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 September 2017 EMA/604559/2017 Human Medicines Evaluation Division Active substance: iron / parenteral preparations Procedure no.: PSUSA/00010236/201701 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/00001584/201702 30 Churchill Place Canary Wharf London E14

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/612350/2018 Human Medicines Evaluation Division Active substance: azelastine Procedure no.: PSUSA/00000277/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Package leaflet: Information for the user. Gemcitabine Fresenius Kabi 40 mg/ml, concentraat voor oplossing voor infusie Gemcitabine

Package leaflet: Information for the user. Gemcitabine Fresenius Kabi 40 mg/ml, concentraat voor oplossing voor infusie Gemcitabine Package leaflet: Information for the user Gemcitabine Fresenius Kabi 40 mg/ml, concentraat voor oplossing voor infusie Gemcitabine Read all of this leaflet carefully before you start using this medicine

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/227889/2018 Human Medicines Evaluation Division Active substance(s): typhoid polysaccharide vaccine Procedure No.: PSUSA/00003065/201708 30 Churchill Place Canary Wharf London E14 5EU

More information

European Medicines Agency decision

European Medicines Agency decision EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for

More information

European Union herbal monograph on Peumus boldus Molina, folium

European Union herbal monograph on Peumus boldus Molina, folium 22 November 2016 EMA/HMPC/453725/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Peumus boldus Molina, folium Final Initial assessment Discussion in Working Party

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion

PACKAGE LEAFLET: INFORMATION FOR THE USER. ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion PACKAGE LEAFLET: INFORMATION FOR THE USER ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion Esmolol hydrochloride Read all of this leaflet carefully before you start using this medicine.

More information

Initial (Full) Marketing Authorisation application accelerated assessment timetables

Initial (Full) Marketing Authorisation application accelerated assessment timetables 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European

More information

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'

More information

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected

More information

European Union herbal monograph on Pistacia lentiscus L., resin (mastix)

European Union herbal monograph on Pistacia lentiscus L., resin (mastix) 7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union

More information

European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix

European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix 05 June 2018 EMA/HMPC/444244/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium Final Initial assessment Discussion in Working

More information

European Union herbal monograph on Agrimonia eupatoria L., herba

European Union herbal monograph on Agrimonia eupatoria L., herba 28 January 2015 EMA/HMPC/680597/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Agrimonia eupatoria L., herba Final Discussion in Working Party on European Union monographs

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user < Invented Name > 10 mg/ml concentrate for solution for infusion (50 mg/ 5 ml, 150 mg/15 ml, 450 mg/45 ml and 600 mg/60 ml) carboplatin Read all of this leaflet

More information

European Union herbal monograph on Eschscholzia californica Cham., herba

European Union herbal monograph on Eschscholzia californica Cham., herba 28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European

More information

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008 European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium

More information

European Union herbal monograph on Ruscus aculeatus L. rhizoma

European Union herbal monograph on Ruscus aculeatus L. rhizoma 30 January 2018 EMA/188804/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Ruscus aculeatus L. rhizoma Draft Initial assessment Discussion in Working Party on European

More information

European Medicines Agency decision

European Medicines Agency decision EMA/357972/2017 European Medicines Agency decision P/0173/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (Colobreathe), (EMEA-000176-PIP01-07-M05)

More information

European Union herbal monograph on Melilotus officinalis (L.) Lam., herba

European Union herbal monograph on Melilotus officinalis (L.) Lam., herba 28 March 2017 EMA/HMPC/44166/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Melilotus officinalis (L.) Lam., herba Draft Initial assessment Discussion in Working

More information

European Union herbal monograph on Glycine max (L.) Merr., lecithinum

European Union herbal monograph on Glycine max (L.) Merr., lecithinum 31 January 2017 EMA/HMPC/220599/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Glycine max (L.) Merr., lecithinum Final Discussion in Working Party on European Union

More information

European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), rhizoma

European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), rhizoma 21 November 2017 EMA/HMPC/329755/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), Draft Initial assessment Discussion in Working

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 31 May 2018 EMA/CHMP/258276/2017 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Dabigatran etexilate, hard capsules, 75 mg, 110 mg and 150 mg productspecific bioequivalence

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 24 January 2018 EMA/270645/2015 Human Medicines Evaluation Division Active substance: azithromycin (systemic use formulations) Procedure no.: PSUSA/00010491/201704 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 26 October 2017 EMA/663700/2017 Human Medicines Evaluation Division Active substance: cromoglicic acid Procedure no.: PSUSA/00000883/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba

European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba 24 November 2015 EMA/HMPC/712511/2014 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba Final Discussion

More information

European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix

European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix 2 February 2016 EMA/HMPC/627057/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix Draft - Revision

More information

European Union herbal monograph on Hedera helix L., folium

European Union herbal monograph on Hedera helix L., folium 21 November 2017 EMA/HMPC/325716/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Hedera helix L., folium Final Initial assessment Discussion in Working Party on European

More information

European Union herbal monograph on Symphytum officinale L., radix

European Union herbal monograph on Symphytum officinale L., radix 5 May 2015 EMA/HMPC/572846/2009 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Symphytum officinale L., radix Final Discussion in Working Party on Community monographs

More information

European Medicines Agency decision

European Medicines Agency decision EMA/574564/2017 European Medicines Agency decision P/0278/2017 of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis vaccine (inactivated,

More information

European Union herbal monograph on Hedera helix L., folium

European Union herbal monograph on Hedera helix L., folium 24 November 2015 EMA/HMPC/586888/2014 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Hedera helix L., folium Final Initial assessment Discussion in Working Party on European

More information

European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos

European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos 29 September 2015 EMA/HMPC/41108/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos Draft Discussion in Working Party on European

More information

Annex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection

Annex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection 07 March 2013 EMA/147828/2013 Patient Health Protection Annex I List of the names, pharmaceutical s, strengths of the medicinal products, routes of, marketing authorisation holders in the member states

More information

European Union herbal monograph on Echinacea pallida (Nutt.) Nutt., radix

European Union herbal monograph on Echinacea pallida (Nutt.) Nutt., radix 05 June 2018 EMA/HMPC/737380/2018 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Echinacea pallida (Nutt.) Nutt., radix Final Initial assessment Discussion in Working

More information

European Union herbal monograph on Ribes nigrum L., folium

European Union herbal monograph on Ribes nigrum L., folium 19 September 2017 EMA/HMPC/745353/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Ribes nigrum L., folium Final Initial assessment Discussion in Working Party on European

More information

European Union herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos

European Union herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos 21 November 2017 EMA/HMPC/327107/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos Draft Initial assessment

More information

Package leaflet: Information for the user. ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion

Package leaflet: Information for the user. ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion Package leaflet: Information for the user ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion Esmolol hydrochloride Read all of this leaflet carefully before you start using

More information

European Union herbal monograph on Origanum majorana L., herba

European Union herbal monograph on Origanum majorana L., herba 20 September 2016 EMA/HMPC/166517/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Origanum majorana L., herba Final Discussion in Working Party on European Union monographs

More information

September 2014 January 2015 March 2015 May 2015 Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation

September 2014 January 2015 March 2015 May 2015 Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation 7 July 2015 EMA/HMPC/39453/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis Draft

More information

European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium

European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium 28 March 2017 EMA/HMPC/750269/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium Draft Initial assessment Discussion in Working

More information

European Medicines Agency decision

European Medicines Agency decision EMA/501681/2016 European Medicines Agency decision P/0213/2016 of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA- 001214-PIP01-11-M05)

More information

European Union herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum

European Union herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum 5 June 2018 EMA/HMPC/753041/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum Final Discussion in Working Party

More information

Community herbal monograph on Viola tricolor L. and/or subspecies Viola arvensis Murray (Gaud) and Viola vulgaris Koch (Oborny), herba cum flore

Community herbal monograph on Viola tricolor L. and/or subspecies Viola arvensis Murray (Gaud) and Viola vulgaris Koch (Oborny), herba cum flore 25 November 2010 EMA/HMPC/131734/2009 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Viola tricolor L. and/or subspecies Viola arvensis Murray (Gaud) and Viola vulgaris Koch

More information

European Medicines Agency decision

European Medicines Agency decision EMA/156109/2018 European Medicines Agency decision P/0103/2018 of 19 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for plazomicin (sulfate) (EMEA-001639-PIP02-17)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/281879/2015 European Medicines Agency decision P/0097/2015 of 8 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human

More information

European Medicines Agency decision

European Medicines Agency decision EMA/120432/2017 European Medicines Agency decision P/0069/2017 of 3 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA-001501-PIP01-13-M04) in

More information

Community herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma

Community herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma 27 January 2011 EMA/HMPC/563408/2010 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma Draft Discussion in Working Party on Community

More information

Draft. Jul 2015 (MLWP) Discussion in Working Party on European Union monographs and list

Draft. Jul 2015 (MLWP) Discussion in Working Party on European Union monographs and list 27 March 2018 EMA/HMPC/432278/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Fragaria vesca L., Fragaria moschata Weston, Fragaria viridis Weston and Fragaria x ananassa

More information

End of consultation (deadline for comments 1 ) 31 October 2015 Rediscussion in MLWP November 2015 Adoption by HMPC 2 February 2016

End of consultation (deadline for comments 1 ) 31 October 2015 Rediscussion in MLWP November 2015 Adoption by HMPC 2 February 2016 2 February 2016 EMA/HMPC/39453/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis raeseri

More information

list (MLWP) September 2009 January 2010

list (MLWP) September 2009 January 2010 25 November 2010 EMA/HMPC/3203/2009 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Quercus robur L., Quercus petraea.(matt.) Liebl., Quercus pubescens Willd., cortex Final

More information

Community herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix

Community herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix 31 March 2011 EMA/HMPC/560961/2010 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Pelargonium sidoides DC and/or Pelargonium Draft Discussion in Working Party on Community

More information

European Medicines Agency decision

European Medicines Agency decision EMA/741983/2016 European Medicines Agency decision P/0324/2016 of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M06)

More information

End of consultation (deadline for comments) 15 August 2012 Rediscussion in Working Party on Community monographs and Community list (MLWP)

End of consultation (deadline for comments) 15 August 2012 Rediscussion in Working Party on Community monographs and Community list (MLWP) 20 November 2012 EMA/HMPC/748220/2011 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Grindelia robusta Nutt., Grindelia squarrosa (Pursh) Dunal, Grindelia humilis Hook. et

More information

Package leaflet: Information for the user. Reminyl 4 mg/ml oral solution. galantamine

Package leaflet: Information for the user. Reminyl 4 mg/ml oral solution. galantamine Package leaflet: Information for the user Reminyl 4 mg/ml oral solution galantamine Read all of this leaflet carefully before you start taking this medicine because if contains important information for

More information

European Union herbal monograph on Echinacea purpurea (L.) Moench, radix

European Union herbal monograph on Echinacea purpurea (L.) Moench, radix 30 May 2017 EMA/HMPC/424583/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Echinacea purpurea (L.) Moench, radix Final Initial assessment Discussion in Working Party

More information

European Union herbal monograph on Salvia officinalis L., folium

European Union herbal monograph on Salvia officinalis L., folium 20 September 2016 EMA/HMPC/277152/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Salvia officinalis L., folium Final Initial assessment Discussion in Working Party

More information

Pharmaceutical Pricing & Reimbursement Information. PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH

Pharmaceutical Pricing & Reimbursement Information. PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH PPRI - Comparative Analysis PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH PPRI Conference Vienna, 29 June 2007 PPRI Conference, Vienna, 29 June 2007 1 Comparative Analysis - Outline

More information